A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis

Thrombosis Research

Volumn 130, Issue 6, 2012, Pages 906-913

  Hayakawa, Mineji ^a   Sawamura, Atsushi ^a   Gando, Satoshi ^a   Jesmin, Subrina ^b   Naito, Sumiyoshi ^c   Ieko, Masahiro ^c  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Disseminated intravascular coagulation (DIC); Fibrinolysis; Neutrophil elastase; Organ dysfunction; Sepsis; Thrombin activatable fibrinolysis inhibitor (TAFI)

Indexed keywords

ALPHA 2 ANTIPLASMIN; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FRUCTOSE BISPHOSPHATE; LEUKOCYTE ELASTASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

APACHE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; HYPOTHESIS; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTHROMBIN TIME; SEPSIS; SEPTIC SHOCK; THROMBOCYTE COUNT;

AGED; CARBOXYPEPTIDASE U; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; SEPSIS;

EID: 84870238343     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.01.015     Document Type: Article

References (38)

1. M. Levi, and H. ten Cate Disseminated intravascular coagulation N Engl J Med 341 1999 586 592
2. F.B. Taylor Jr., C.H. Toh, W.K. Hoot, H. Wada, and M. Levi Toward definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Thromb Haemost 86 2001 1327 1330
3. S. Madoiwa, S. Nunomiya, T. Ono, Y. Shintani, T. Ohmori, and J. Mimuro Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation Int J Hematol 84 2006 398 405
4. K.J. Hartemink, C.E. Hack, and A.B.J. Groeneveld Relation between coagulation/fibrinolysis and lactate in the course of human septic shock J Clin Pathol 63 2010 1021 1026
5. H. Asakura, Y. Ontachi, T. Mizutani, M. Kato, M. Saito, and I. Kumabashiri An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation Crit Care Med 29 2001 1164 1168
6. S. Gando, M. Hayakawa, A. Sawamura, H. Hoshino, A. Oshiro, and N. Kubota The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation Thromb Res 121 2007 67 73
7. E.F. Plow The major fibrinolytic proteases of human leucocytes Biochim Biophys Acta 630 1980 47 56
8. C.W. Francis, and V.J. Marder Degradation of cross-linked fibrin by human leukocyte proteases J Lab Clin Med 107 1986 342 352
9. I. Kohono, K. Inuzuka, Y. Itoh, K. Nakahata, Y. Eguchi, and T. Sugo A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin: its application to the measurement of granulocyte-derived elastase digests in plasma Blood 95 2000 1721 1728
10. B.N. Bouma, and J.C.M. Meijers Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) J Thromb Haemost 1 2003 1566 1574
11. T. Kawanuma, N. Okada, and H. Okada Elastase from activated human neutrophils activates procarboxypeptidase R Microbiol Immunol 46 2002 225 230
12. R. Watanabe, H. Wada, Y. Watanabe, M. Sakakura, T. Nakasaki, and Y. Mori Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation Thromb Res 104 2001 1 6
13. C.C. Chen, K.D. Lee, J.P. Gau, Y.B. Yu, J.Y. You, and S.H. Lee Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation Ann Hematol 84 2005 675 680
14. S. Zeeleder, V. Shroeder, C.E. Hack, H.P. Kohler, and W.A. Wuillemin TAFI and PAI-1 levels in human sepsis Thromb Res 118 2006 205 212
15. M. Emonts, E.L.E. de Bruijne, A.H.C. Guimaraes, P.J. Declerck, F.W.G. Leebeek, and M.P.M. de Maat Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children J Thromb Haemost 6 2008 268 276
16. M. Skeppholm, N.H. Wallén, F. Mobarrez, A. Sollevi, A. Soop, and J.P. Antovic Inflammation and thrombin generation causes increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia Blood Coagul Fibrinolysis 20 2009 611 613
17. W.A. Knaus, E.A. Draper, D.P. Wanger, and J.E. Zimmerman APACHE II: A severity classification system Crit Care Med 13 1985 818 829
18. F.L. Ferreira, D.P. Bota, A. Bross, C. Mélot, and J.L. Vincent Serial evaluation of the SOFA score to predict outcome in critically ill patients JAMA 286 2001 1754 1758
19. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definition for sepsis and organ failure and guidelines for the use innovative therapies in sepsis Crit Care Med 20 1992 864 874
20. S. Gando, D. Saitoh, H. Ogura, T. Mayumi, K. Koseki, and T. Ikeda Japanese Association for Acute Medicine disseminated intravascular coagulation (JAAM DIC) study group. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey Crit Care Med 36 2008 145 150
21. H. Asakura, H. Jokaji, M. Saito, C. Uotani, I. Kumabashiri, and E. Morishita Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation Am J Hematol 36 1991 176 183
22. W.L. Chandler, M.C. Alessi, M.F. Aillaud, P. Henderson, P. Vague, and I. Juhan-Vague Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels Circulation 96 1997 761 768
23. H. Bounameaux, and E.K.O. Ktuithof On the association of elevated tPA/PAI-1 complex and von Willbrand factor with recurrent myocardial infarction Arterioscler Thromb Vasc Biol 20 2000 1857 1859
24. S. Gando, S. Nanzaki, S. Sasaki, K. Aoi, and O. Kemmotsu Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock Crit Care Med 26 1998 1005 1009
25. E.C.M. van Gorp, M.C. Minnema, C. Suharti, A.T.A. Mairuhu, D.P.M. Brandjes, and H. ten Cate Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever Br J Haematol 113 2001 94 99
26. M.B. Boffa, and M.L. Koschinsky Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles Clin Biochem 40 2007 431 442
27. E. Ceresa, E. Brouwers, M. Peeters, C. Jean, P.J. Declerck, and A. Gils Development of ELISAs measuring the extent of TAFI activation Arterioscler Thromb Vasc Biol 26 2006 423 428
28. T.M. Binette, F.B. Taylor Jr., G. Peer, and L. Bajzar Thrombin-thrombmodulin connects coagulation and fibrinolysis: more than an in vivo phenomenon Blood 110 2007 3168 3175
29. L.L.K. Leung, T. Myles, T. Nishimura, J.J. Song, and W.H. Robinson Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI) Mol Immunol 45 2008 4080 4083
30. Y. Muto, K. Suzuki, H. Iida, S. Sakakibara, E. Kato, and F. Itoh EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats Crit Care Med 37 2009 1744 1749
31. M.E. Meltzer, C.J.M. Doggen, P.G. de Groot, J.C.M. Meijers, F.R. Rosendaal, and T. Lisman Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a myocardial infarction in men Haematologica 94 2009 811 818
32. S. Neuman, G. Gunter, N. Hennrich, and H. Lang PMN-elastase assay enzyme immunoassay for human polymorphonuclear elastase complexed with alpha1-proteinase inhibitor J Clin Chem Clin Biochem 22 1984 693 697
33. S. Gando, T. Kameue, N. Matsuda, M. Hayakawa, H. Hoshino, and H. Kato Serial changes in neutrophil-endothelial activation markers during the course of sepsis associated with disseminated intravascular coagulation Thromb Res 116 2005 91 100
34. S. Madoiwa, H. Tanaka, Y. Nagahama, M. Dokai, Y. Kashiwakura, and A. Ishiwata Degradation of cross-linked fibrin by leucocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation Thromb Res 127 2011 349 355
35. C. Taggart, D. Cervantes-Laurean, G. Kim, N.G. MacElvaney, N. Wehr, and J. Moss Oxidation of either Methionine 351 or Methionine 358 in alpha1-antitripsin causes loss of antineutrophil elastase activity J Biol Chem 275 2000 27258 27265
36. J. Gombâs, K. Kolev, E. Tarjan, and R. Machovich Impaired fibrinolytic potential related to elevated alpha1-proteinase inhibitor levels in patients with pulmonary thromboembolism Ann Hematol 83 2004 759 763
37. Y. Kamikura, H. Wada, T. Nobori, T. Matsumoto, H. Shiku, and K. Ishikura Elevated levels of fibrin degradation products by granulocyte-derived elastase in patients with deep vein thrombosis Thromb Res 115 2005 53 57
38. S. Gando, T. Kameue, A. Sawamura, M. Hayakawa, H. Hoshino, and N. Kubota An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery Thromb Res 120 2007 87 93